Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SIRP alphaV2

SIRP alphaV2

Brief Information

Name:Signal-regulatory protein alpha
Target Synonym:SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Recept
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human SIRP alphaV2 (31-148), Llama IgG2b Fc Tag (Cat. No. SI2-H5257) at 5 μg/mL (100 μL/well) can bind Human CD47, His Tag (Cat. No. CD7-H5227) with a linear range of 0.02-0.313 μg/mL (QC tested).

SIRP alphaV2 MALS images

The purity of Human SIRP alphaV2, Llama IgG2b Fc Tag (Cat. No. SI2-H5255) is more than 90% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Synonym Name



Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

Clinical and Translational Updates

    Public Drug Information

    Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
    Relugolix/Estradiol/Norethindrone Acetate E2/NETA Approved Myovant Sciences MYFEMBREE, RYEQO United States Menorrhagia; Leiomyoma Myovant Sciences 2021-05-26 Pain; Endometriosis; Leiomyoma; Menorrhagia; Uterine Neoplasms Details
    Elagolix/estradiol/norethindrone acetate Approved Abbvie Inc Oriahnn United States Menorrhagia Abbvie Inc 2020-05-29 Menorrhagia Details

    Clinical Drug Information

    Name Research Code Research Phase Company Indications Clinical Trials
    IBC-0966 IBC-0966 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Neoplasms Details
    BI-765063 OSE-172; BI-765063 Phase 1 Clinical Ose Immunotherapeutics Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
    Anzurstobart BMS-986351; CC-95251 Phase 1 Clinical Celgene Corp Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
    ADU-1805 ADU-1805 Phase 1 Clinical Aduro Biotech Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
    LM-101 LM-101 Phase 1 Clinical LaNova Medicines Ltd Leukemia; Solid tumours; Hematologic Neoplasms; Neoplasms Details
    Q-1801 Q-1801; Q 1801 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours Details
    Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo) DS-1103a Phase 1 Clinical Daiichi Sankyo Co Ltd Solid tumours; Breast Neoplasms Details
    ELA-026 ELA-026 Phase 1 Clinical Electra Therapeutics Inc Lymphohistiocytosis, Hemophagocytic Details
    BYON-4228 BYON-4228 Phase 1 Clinical Byondis Bv Solid tumours; Lymphoma Details
    BSI-082 BSI-082 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd Hematologic Neoplasms; Solid tumours Details
    BR-105 BR-105; BR105 Phase 1 Clinical BioRay Pharmaceutical Co Ltd, Hisun Biopharmaceutical Co Ltd Neoplasms Details
    [89Zr]Zr- BI-765063(Boehringer Ingelheim) Phase 1 Clinical Boehringer Ingelheim Corp Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma Details
    TQB-2928 TQB-2928 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute Details
    BI-765080 Phase 1 Clinical C.H. Boehringer Sohn Ag & Co. Kg Details
    ES-004 ES-004; ES 004-N4; ES 004-B4 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms Details

    This web search service is supported by Google Inc.

    Call us
    Call us
    North America:
    +1 800-810-0816 (Toll Free)
    Asia & Pacific:
    +86 400-682-2521
    +1 888-377-6111
    1 Innovation Way, Newark, DE 19711, USA

    Leave a message